SCHEMBL3146350

SCHEMBL3146350

CCCCCCC(C)NCC

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.54
ADH1C P00326 1/20 0.54
ADH1A P07327 1/20 0.54
ADH4 P08319 1/20 0.54
ADH7 P40394 1/20 0.54
OPRM1 P35372 1/20 0.44
ADRB2 P07550 6/20 0.43
SPHK1 Q9NYA1 1/20 0.41
LMNA P02545 1/20 0.41
DNM1 Q05193 2/20 0.40
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.40
ACE2 Q9BYF1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27625456 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL2310099 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL19621284 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL10066725 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL15534730 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL2360620 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL7762311 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL17104353 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL9204901 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL27938946 1.00 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3924628-B1 LOAD-RELIEVING DEVICE KSB SE & CO KGAA (DE) 2024-01-24 EP disclosed
US-11702432-B2 Method of making an organoaminosilane DOW SILICONES CORPORATION (US) 2023-07-18 US disclosed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20230002436-A1 MODIFIED NUCLEOTIDES AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2023-01-05 US disclosed
EP-3390410-B1 METHODS OF MAKING HIGH PURITY TRISILYLAMINE NATA SEMICONDUCTOR MAT CO LTD (CN) 2022-02-02 EP disclosed
US-20220023997-A1 SYNTHETIC GRINDSTONE TOKYO DIAMOND TOOLS MFG. CO., LTD. (JP) 2022-01-27 US disclosed
WO-2021240099-A1 COUPLED TERPENE CONJUGATE LABORATOIRES ERIGER (FR) 2021-12-02 WO disclosed
US-11111256-B2 High purity trisilylamine, methods of making, and use JIANGSU NATA OPTO-ELECTRONIC MATERIALS CO. LTD. (CN) 2021-09-07 US disclosed
CN-108602839-B A process for preparing an organoaminosilane; method for producing silylamines from organoaminosilanes 南大光电半导体材料有限公司 2021-06-29 CN disclosed
CN-108602840-B High purity trisilylamine, preparation method and use 南大光电半导体材料有限公司 2021-05-28 CN disclosed
US-5811411-A Fungicides for the control of take-all disease of plants MONSANTO COMPANY (US) 1998-09-22 US disclosed
US-5705513-A HETEROCYCLIC FUNGICIDES WITH PYRIDINE OR FURAN RINGS MONSANTO COMPANY (US) 1998-01-06 US disclosed
US-5693667-A Fungicides for the control of take-all disease of plants MONSANTO COMPANY (US) 1997-12-02 US disclosed
EP-0619297-B1 Fungicides for the control of take-all desease of plants MONSANTO CO (US) 1997-06-18 EP disclosed
US-5498630-A SUBSTITUTED BENZOTHIOPHENECARBOXAMIDES MONSANTO COMPANY (US) 1996-03-12 US disclosed
EP-0619297-A1 Fungicides for the control of take-all desease of plants MONSANTO COMPANY (US) 1994-10-12 EP disclosed
WO-1993007751-A1 FUNGICIDES FOR THE CONTROL OF TAKE-ALL DISEASE OF PLANTS MONSANTO COMPANY (US) 1993-04-29 WO disclosed
EP-0538231-A1 Fungicides for the control of take-all disease of plants MONSANTO COMPANY (US) 1993-04-21 EP disclosed
EP-0288819-B1 PROCESS FOR THE PREPARATION OF DIALKYLDITHIOCARBAMATES OF POLYVALENT METALS C.F. Spiess & Sohn GmbH & Co. Chemische Fabrik (DE) 1991-07-17 EP disclosed
US-3988249-A Extreme pressure additive for lubricants UNIROYAL INC. (US) 1976-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ADH1B 3094/4885ADH1C 4321/4885ADH1A 4306/4885
US-20230002436-A1 MODIFIED NUCLEOTIDES AND USES THEREOF NUDT1, RNMT, ADAR ADH1B 250/4885ADH1C 3076/4885ADH1A 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.